Biocon’s, partner FUJIFILM Pharma Co., (FFP) has launched Insulin Glargine in Japan on July 15, 2016. This is pursuant to receiving approval for its Insulin Glargine from the Japanese regulator last quarter. Insulin Glargine BS Injection Kit (FFP) has been developed & manufactured by Biocon, and is being commercialized by FFP in Japan.
The product is a ready-to-use, prefilled disposable pen with 3 ml of 100IU Insulin Glargine. It will provide a high quality, yet affordable, world-class long-acting biosimilar basal Insulin Glargine for patients of diabetes in Japan. According to the International Diabetes Federation, there were 7.2 million people with diabetes in Japan in 2015.
The company through its partner aims to capture a significant share of the Japanese Glargine market of $144 million, which is the second largest market outside of North America & Europe and is largely dominated by disposable pens.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
